Incidence of Invasive Pneumococcal Disease (IPD) in Children by Risk Status in the United States, 2010-2022

Salini Mohanty, Merck & Co., Inc., Holland, PA, United States; Nicolae Done, Analysis Group, Boston, MA, United States; Yan Song, Analysis Group, Boston, MA, United States; Travis Wang, Analysis Group, Boston, MA, United States; Abigail Zion, Analysis Group, Inc., Boston, MA, United States; Meghan White, Merck Sharp & Dohme, LLC, North Wales, PA, United States; Yi-Ling Huang, Merck, Rahway, NJ, United States; Kelsie Cassell, Merck, Philadelphia, PA, United States; Kelly D Johnson, Merck & Co., Inc., Philadelphia, PA, United States; Natalie Banniettis, Pharmaceutical Industry, Maple Glen, PA, United States; Jessica P Weaver, Merck & Co. Inc., Fanwood, NJ, United States; Kristen A ALLYSN. Feemster, Merck (Merck Sharp & Donhme a subsidiary of Merck & Co, Inc.), Philadelphia, PA, United States